Rob Surgical announces €5m investment from Scranton Enterprises

– SPAIN, Barcelona – Rob Surgical today announced that the company has closed a €5 million investment round with the Dutch holding Scranton Enterprises to fund the final phase of the new Bitrack System and launch the product on the market.

The Bitrack System will be an alternative to the current laparoscopy surgical robot Da Vinci, and will be an improvement on what is currently available in terms of efficiency.

“This investment will allow us to obtain CE certification in 30 months,” said Jaume Amat, CEO of Rob Surgical and president of CataloniaBio & HealthTech.

“The value proposition that differentiates us from other surgical robots is based on three cornerstones: high precision benefiting the patient, superior usability for the surgeon and a significant total cost of ownership reduction benefiting hospitals”, explains Amat.

To achieve this, the Rob Surgical engineers, led by the professors Josep Amat and Alícia Casals, have designed a flexible, modular and open robotic platform that “will improve the effectiveness of today’s robotic surgery and make it accessible to more hospitals around the world”, adds Jaume Amat. “We will make possible combined manual and robotic surgery, what we like to call hybrid minimum invasive surgery (HMIS)” says Amat.

The new robot has already been technically validated in experimental models, used by surgeons from the Mayo Clinic (United States) and the Barcelona university hospitals Clinic, Vall d’Hebron and Germans Trias. Between 2019 and 2021 Rob Surgical will build three new units to finalize the validation and industrialization process, will expand the corporate and engineering team and will conduct the final safety and functionality trials.

- DisclaimerNews, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.

Comments are closed.